TNFi cycling more costly than switching MOA in RA
In patients with rheumatoid arthritis (RA) who have failed tumour necrosis factor inhibitor (TNFi) treatment, cycling to another TNFi appears to be associated with greater healthcare costs than switching to a diseasemodifying antirheumatic drug with another mechanism of action (MOA), according to findings of a Sanofi- and Regeneron Pharmaceuticals-funded study published in Advances in Therapy. Optum Research Database Commercial and Medicare Advantage claims data were used to assess treatment persistence and healthcare costs in patients with RA who had at least one claim for a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab) between January 2012 and September 2015, and who switched to another TNFi or a therapy with a different MOA (abatacept, tocilizumab or tofacitinib) within a year..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - (2017), 790, Seite 33-33 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1999601076 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1999601076 | ||
| 003 | DE-627 | ||
| 005 | 20230512080552.0 | ||
| 007 | tu | ||
| 008 | 171228s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1999601076 | ||
| 035 | |a (DE-599)GBVOLC1999601076 | ||
| 035 | |a (PRQ)proquest_journals_19737430770 | ||
| 035 | |a (KEY)0248955420170000000079000033tnficyclingmorecostlythanswitchingmoainra | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a TNFi cycling more costly than switching MOA in RA |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a In patients with rheumatoid arthritis (RA) who have failed tumour necrosis factor inhibitor (TNFi) treatment, cycling to another TNFi appears to be associated with greater healthcare costs than switching to a diseasemodifying antirheumatic drug with another mechanism of action (MOA), according to findings of a Sanofi- and Regeneron Pharmaceuticals-funded study published in Advances in Therapy. Optum Research Database Commercial and Medicare Advantage claims data were used to assess treatment persistence and healthcare costs in patients with RA who had at least one claim for a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab) between January 2012 and September 2015, and who switched to another TNFi or a therapy with a different MOA (abatacept, tocilizumab or tofacitinib) within a year. | ||
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Patients | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Auckland : Wolters Kluwer Health Adis, 1996 |g (2017), 790, Seite 33-33 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:790 |g pages:33-33 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1973743077 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 |e 790 |h 33-33 | ||